Your browser doesn't support javascript.
loading
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams, David; Tournev, Ivailo L; Taylor, Mark S; Coelho, Teresa; Planté-Bordeneuve, Violaine; Berk, John L; González-Duarte, Alejandra; Gillmore, Julian D; Low, Soon-Chai; Sekijima, Yoshiki; Obici, Laura; Chen, Chongshu; Badri, Prajakta; Arum, Seth M; Vest, John; Polydefkis, Michael.
Afiliação
  • Adams D; Neurology Department, CHU Bicêtre, APHP, Université Paris-Saclay, Le Kremlin Bicêtre Cedex, France.
  • Tournev IL; Department of Neurology, Clinic of Nervous Diseases, University Hospital Aleksandrovska, Medical University, Sofia, Bulgaria.
  • Taylor MS; Department of Cognitive Sciences, New Bulgarian University, Sofia, Bulgaria.
  • Coelho T; Department of Clinical Immunology and Allergy, Westmead Hospital and Westmead Clinical School, University of Sydney, Sydney, NSW, Australia.
  • Planté-Bordeneuve V; Hospital de Santo António, Centro Hospitalar Universitário do Porto, Porto, Portugal.
  • Berk JL; Neurology - Amyloid Network, CHU Henri Mondor, APHP, University Paris Est - Créteil, Créteil, France.
  • González-Duarte A; Boston Medical Center, Boston University, Boston, Massachusetts, USA.
  • Gillmore JD; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, D.F., México.
  • Low SC; National Amyloidosis Centre, University College London, Royal Free Hospital, London, UK.
  • Sekijima Y; Department of Medicine, Division of Neurology, University Malaya Medical Centre, Kuala Lumpur, Malaysia.
  • Obici L; Department of Medicine (Neurology & Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
  • Chen C; Amyloidosis Research and Treatment Centre, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
  • Badri P; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Arum SM; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Vest J; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Polydefkis M; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Amyloid ; 30(1): 1-9, 2023 Mar.
Article em En | MEDLINE | ID: mdl-35875890
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_endocrine_disorders Assunto principal: Polineuropatias / Neuropatias Amiloides Familiares Tipo de estudo: Clinical_trials Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Amyloid Assunto da revista: BIOQUIMICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_endocrine_disorders Assunto principal: Polineuropatias / Neuropatias Amiloides Familiares Tipo de estudo: Clinical_trials Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Amyloid Assunto da revista: BIOQUIMICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França